$13.48
-0.59-4.19%
最終更新: Oct 30, 4:02 PM
Benzinga
Benzinga
Benzinga
土曜日, 10 31
Benzinga
© 2026 Benzinga | All Rights Reserved
Crescent Biopharma (CBIO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.67 | $-0.80 | $-2.58 | $-1.23 |
| Actual | $-0.74 | $-0.70 | $-4.01 | $-1.27 |
| Surprise | -10.4% | +12.5% | -55.4% | -3.25% |
| Revenue | ||||
| Estimate | $357140 | $357140 | $12.5M | — |
| Actual | $0 | $1.0M | $10.8M | $0 |
| Surprise | -100.0% | +190.9% | -13.3% | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.60 | $-0.64 | $-0.86 | $-0.91 |
| Revenue | ||||
| Consensus | $357140 | $357140 | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $-0.74 | $-0.67 | -10.4 % |
| Q1 | Apr 29, 2026 | $-0.70 | $-0.80 | 12.5 % |
| Q4 | Feb 26, 2026 | $-4.01 | $-2.58 | -55.4 % |
| Q3 | Nov 6, 2025 | $-1.27 | $-1.23 | -3.25 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $0 | $357.14K | -100.0 % |
| Q1 | Apr 29, 2026 | $1.04M | $357.14K | 190.9 % |
| Q4 | Feb 26, 2026 | $10.84M | $12.50M | -13.3 % |